Clinical Outcomes: Health Economics

ADVANCING CARE WHILE REDUCING COSTS

Abstracts, Posters, Presentations, and Publications

Real-world health economics data support RECELL® System cost savings for burn treatment.

Presentation Abstracts

  • Chihade. Autologous Epidermal Skin Cell Suspension: A Cost-Effective Treatment for Burns >20% TBSA in a County Hospital with Limited Resources. 2020 Southern Region Burn Conference.
  • Foster. The Changing State of US Burn Care: Summarizing Current Burn Care Trends and Valuing New Interventions. 2020 American Burn Association.
  • Foster K, Bilir P, Kruger E, Kowal S, IV JHH, Hickerson W, Nystrom S, Turley D, Sparks J, Iyer N, Quick A. Abstract: Cost-effectiveness (CE) of an Autologous Regenerative Epithelial Suspension (RES) versus Standard of Care (SOC) for Treatment of Severe Burns in the United States. ABA 2018; 2018 June; Chicago, IL.
  • Jeremiah Sparks, Andrew Quick, Eliza Kruger, Stacey Kowal. Resource Use, Costs and Outcomes for Treatment of Severe Burns Using RECELL®. Southern Regional Burn Congress; 2018 November; Mobile, AL.
  • Blake Platt,, Colombe Castellucci, Jeffrey E. Carter. Autologous Skin Cell Suspension Reduces Length of Stay for Burn Injuries. Louisiana American College of Surgeons 2019 January; New Orleans, LA.
  • Foster K, Kruger E, Bilir SP, Kowal S, Sparks J, Iyer N, Quick A. Burn Care Health Economic Model: Evaluation of Resource Use and Costs from Treatment of Severe Burns Using RECELL® System. 41st Annual Boswick Burn & Symposium [Podium Presentation]. 2019 February; Maui, HI.
  • Foster K, Kruger E, Kowal S, Bilir S, Nystrom S, Sparks J, Bush K, Iyer N, Quick A. 381 Budget Impact of Autologous Cell Harvesting Device (ACHD) Use versus Standard of Care (SOC) for Treatment of Severe Burns: A Case Study. Journal of Burn Care & Research. 2019 Mar 8;40(Supplement_1):S165-6.
  • Kruger E, Bilir SP, Kowal S, Han E. Relationship Between Patient Characteristics and Length of Stay for Severe Burn Patients: Analysis of the American Burn Association National Burn Repository. Value in Health. 2018 May 1;21:S109-10.
  • Bilir SP, Kruger E, Kowal S, Holmes IV H, Hickerson W, Foster K, Nystrom SV, Turley DM, Sparks J, Iyer N, Quick A. Inpatient Cost of Acute Care for Severe Burn Patients: Validation of Economic Model for Adults and Children. Value in Health. 2018 May 1;21:S215.
  • Khandelwal A, Kowal S, Ferrufino C, Walsh T, Sparks J. Assessing the health economic outcomes associated with autologous skin cell suspension (ASCS) use using real world national and regional data for definitive closure. Eastern Great Lakes Regional Burn Congress. 2019 September; Pittsburgh, PA.
  • Litt J, Kowal S, Ferrufino C, Walsh T, Sparks J. Evaluating real world national and regional definitive closure trends in burn care, including health economic outcomes with autologous skin cell suspension use. Midwest Regional Burn Congress. 2019 October; Iowa City, IA.
  • Savetamal A, Kowal S, Ferrufino C, Walsh T, Sparks J. Evaluating the health economic outcomes of autologous skin cell suspension (ASCS) using real world national and regional benchmark data. Northeast Regional Burn Congress; 2019 November; Portland, ME.
  • Hickerson WL, Kowal S, Ferrufino C, Walsh T, Sparks J. Evaluating real world national and regional definitive closure trends in burn care, including health economic outcomes with autologous skin cell suspension use. Southern Regional Burn Congress; 2019 December; San Antonio, TX.
  • Blake Platt, Jeffrey E. Carter Autologous Skin Cell Suspension Reduces Length of Stay for Burn Injuries. EAST (Association for the Surgery of Trauma); 2020 January; Orlando, FL.
  • Kevin N Foster, Jeremiah Sparks, Tom Walsh, Cheryl Ferrufino, Stacey Kowal, Pratyusha Vadagam. Health Economic Assessment of Autologous Skin Cell Suspension using Contemporary Real-World Burn Care Data. Boswick Symposium. 2020 January; Maui, HI.
  • Alisa Savetamal, Jeremiah Sparks, Tom Walsh, Cheryl Ferrufino, Stacey Kowal, Pratyusha Vadagam. Analysis of Current Real-World Burn Care Practice Patterns Compared to National Burn Registry. Boswick Symposium. 2020 January; Hawaii.
  • Jeffrey Litt, Stacey Kowal, Cheryl P Ferrufino, Tom Walsh, Jeremiah Sparks. Evaluating current real-world national and regional definitive closure trends in burn care, including health economic outcomes with autologous skin cell suspension use. North American Burn Society Meeting. 2020 February; Sun Valley, ID.
  • James Hill Holmes IV, Stacey Kowal, Cheryl Ferrufino, Tom Walsh, Jeremiah Sparks. Real World Treatment Trends for Patients Total Body Surface Area (TBSA) ≤ 20%: Evaluating Important Shifts in Care and Budget Impact of Autologous Stem Cell Suspension (ASCS) Adoption. American Burn Association 52nd Annual Meeting 2020 March; Orlando, FL.
  • Stacey Kowal, Eliza Kruger, Pinar Bilir, Bill Hickerson, James Holmes, Kevin Foster. Relationship between Patient Characteristics and Number of Procedures as well as Length of Stay for Patients Surviving Severe Burn Injuries: Analysis of the American Burn Association National Burn Repository. American Burn Association 52nd Annual Meeting 2020 March; Orlando.
  • Kowal S, Hickerson B, Narayan I. The Use and Value of Health Economics in Burn Care. American Burn Association 52nd Annual Meeting (Orlando, FL). March 2020. [90-minute educational symposia led in partnership with ABA president elect and BARDA/HHS Burn Chief]
  • William L. Hickerson, Stacey Kowal, Cheryl P Ferrufino, Pratyusha Vadagam, Tom Walsh, Jeremiah Sparks. Current real-world trends in burn care in the United States (U.S.), including health economic outcomes with autologous skin cell suspension (ASCS) use. International Society for Burn Injuries. 2020 August; Birmingham, UK.

Publications

For additional information, please review our Abstract and Publications libraries.

PATIENT OUTCOMES

AVITA icons abstracts

ABSTRACTS

AVITA icons publications

PUBLICATIONS

AVITA icons abstracts

VIDEOS

AVITA icons abstracts

HEALTH ECONOMICS

IMPORTANT SAFETY INFORMATION (United States)

INDICATIONS FOR USE: The RECELL® Autologous Cell Harvesting Device is indicated for the treatment of acute thermal burn wounds. The RECELL® device is used by an appropriately-licensed healthcare professional at the patient’s point of care to prepare autologous RES® Regenerative Epidermal Suspension for direct application to acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients.

CONTRAINDICATIONS: RECELL® is contraindicated for: the treatment of wounds clinically diagnosed as infected or with necrotic tissue, the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate (Hartmann’s) solution, patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions.

WARNINGS AND PRECAUTIONS: Autologous use only. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL® is provided sterile and is intended for single-use. Do not use if packaging is damaged or expired. Choose a donor site with no evidence of cellulitis or infection and process skin immediately. A skin sample should require between 15 and 30 minutes contact with Enzyme. Contact in excess of 60 minutes is not recommended. RECELL® Enzyme is animal derived and freedom from infectious agents cannot be guaranteed.

PRECAUTIONS: RECELL® is not intended for use without meshed autograft for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL® without meshed autograft have not been established for treatment of partial-thickness burn wounds: on the hands and articulating joints, >320 cm2, in patients with wounds totaling >20% total body surface area (TBSA). The safety and effectiveness of RECELL with autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulated joints, and in patients younger than 28 days of age (neonates).

SPECIAL PATIENT POPULATIONS: The safety and effectiveness of RECELL® have not been established for treatment of acute thermal partial-thickness burn wounds in pediatric patients younger than 18 years of age.

For complete Important Safety Information, refer to Instructions For Use. Please be aware that any indication for RECELL® outside of the United States may differ from the US indication. Please see the Instructions for Use for each country for the specific indication of RECELL®.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to AVITA, its subsidiaries or affiliates. No use of any AVITA trademark, trade name, or trade dress in this site may be made without the prior written authorization of AVITA, except to identify the product or services of the company.
©Copyright 2022 AVITA Medical. All Rights Reserved.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to AVITA, its subsidiaries or affiliates. No use of any AVITA trademark, trade name, or trade dress in this site may be made without the prior written authorization of AVITA, except to identify the product or services of the company.
©Copyright 2022 AVITA Medical. All Rights Reserved.